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Background: The involvement of protein kinase CK2 in sustaining cancer cell survival could have implications also
in the resistance to conventional and unconventional therapies. Moreover, CK2 role in blood tumors is rapidly
emerging and this kinase has been recognized as a potential therapeutic target. Phase I clinical trials with the oral
small ATP-competitive CK2 inhibitor CX-4945 are currently ongoing in solid tumors and multiple myeloma.
Methods: We have analyzed the expression of CK2 in acute myeloid leukemia and its function in cell growth and
in the response to the chemotherapeutic agent daunorubicin We employed acute myeloid leukemia cell lines and
primary blasts from patients grouped according to the European LeukemiaNet risk classification. Cell survival,
apoptosis and sensitivity to daunorubicin were assessed by different means. p53-dependent CK2-inhibition-induced
apoptosis was investigated in p53 wild-type and mutant cells.
Results: CK2α was found highly expressed in the majority of samples across the different acute myeloid leukemia
prognostic subgroups as compared to normal CD34+ hematopoietic and bone marrow cells. Inhibition of CK2 with
CX-4945, K27 or siRNAs caused a p53-dependent acute myeloid leukemia cell apoptosis. CK2 inhibition was
associated with a synergistic increase of the cytotoxic effects of daunorubicin. Baseline and daunorubicin-induced
STAT3 activation was hampered upon CK2 blockade.
Conclusions: These results suggest that CK2 is over expressed across the different acute myeloid leukemia subsets
and acts as an important regulator of acute myeloid leukemia cell survival. CK2 negative regulation of the protein
levels of tumor suppressor p53 and activation of the STAT3 anti-apoptotic pathway might antagonize apoptosis
and could be involved in acute myeloid leukemia cell resistance to daunorubicin.
Keywords: Acute myeloid leukemia, Kinase inhibitors, Protein kinase CK2, CX-4945, p53, Daunorubicin, STAT3,
Apoptosis* Correspondence: carmela.gurrieri@unipd.it; g.semenzato@unipd.it
†Equal contributors
1Department of Medicine, Hematology-Clinical Immunology Branch, and
Venetian Institute of Molecular Medicine, Hematological Malignancies Unit,
University of Padova School of Medicine, Padova, Italy
Full list of author information is available at the end of the article
© 2013 Quotti Tubi et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Quotti Tubi et al. Journal of Hematology & Oncology 2013, 6:78 Page 2 of 15
http://www.jhoonline.org/content/6/1/78Background
Acute myeloid leukemia (AML) is characterized by the un-
controlled growth of a neoplastic clone of immature mye-
loid precursors in the bone marrow and in the blood
stream. AML encompasses an array of biologically distinct
diseases that differ with regard to the pathogenesis, clinical
course, response to therapy and prognosis [1]. AML may
arise de novo or as a secondary cancer in patients previ-
ously treated with chemotherapy and/or radiotherapy (ther-
apy-related AML). Malignant clones that are endowed with
the capability of escaping spontaneous and drug-induced
programmed cell death are selected during the course of
the disease. AML - initially responsive to chemotherapy -
in a large proportion of cases becomes subsequently refrac-
tory to drug-induced apoptosis. Thus, a critical research
goal is the identification of the molecular mechanisms ac-
counting for uncontrolled AML cell growth and resistance
to apoptosis in order to design novel, molecularly based,
targeted therapies [2,3].
Protein kinase CK2 is a ubiquitous serine-threonine kin-
ase involved in a multitude of cellular processes. CK2 is a
tetramer enzyme composed most often by two catalytic
subunits (α or α’, encoded by separate genes) and two regu-
latory subunits (β), so that the possible species in the cell
are α2β2 or αα’β2 [4]. CK2 phosphorylates a large number
of substrates with disparate functions [5]. Deletion of
CK2α and β in mice is embryonic lethal [6] and knock out
of CK2α’ results in globozoospermia and other defects [7].
A remarkable feature of CK2 is the frequent over expres-
sion and high enzymatic activity displayed in different types
of solid tumors. Indeed, CK2 has been demonstrated to
contribute to the malignant phenotype and tumor progres-
sion in mouse models as well as in human cancer cells [8].
To this regard, a peculiar property of CK2 is the ability to
protect cells from apoptosis [9]. This action is believed to
rely on several mechanisms. For instance, CK2 interferes
with tumor suppressor PML and PTEN protein stability
and function by phosphorylating critical serine residues on
these proteins and rendering them less active: in the case
of PML through enhanced proteasome-mediated degrad-
ation, in the case of PTEN through the stabilization of a
less active form of the molecule [10,11]. Moreover, CK2
phosphorylation of anti-apoptotic molecules contributes to
protection from apoptosis. CK2 targets Apoptosis Repres-
sor with Caspase Recruiting domain (ARC), shifting the
molecule to the mitochondria where it inhibits caspase 8
[12]. Also, CK2 phosphorylation of BID protects it from
caspase 8 cleavage and cell death [13]. In addition to this,
CK2 positively regulates growth-promoting cascades, such
as the PI3K/AKT [14], the NF-κB, the JAK/STAT and the
Wnt/β-catenin signaling pathways with the result of
strongly directing cell fate towards survival and against
programmed cell death [15]. Interestingly, a recently pro-
posed unifying model for CK2 function relies on theregulation of the CDC37/HSP90 chaperone complex
through Ser13 phosphorylation on CDC37 [16]. This
modification is essential for the chaperoning activity of
HSP90 directed towards an array of client protein kinases,
many of which are oncogenic. CK2 has also been involved
in the cellular DNA damage response, since it was shown
that this kinase can regulate both single strand and double
strand DNA break repair, by facilitating the XRCC1 func-
tion [17] and the UV light response by activating the NF-
κB pathway and phosphorylating the high mobility group
protein SSRP1 [18,19]. Taken together, the established role
played by CK2 in tumorigenesis, could rely on the extraor-
dinary property of this kinase to “addict” cells towards an
apoptosis-resistant, proliferation and DNA damage repair-
prone-phenotype [20].
However, whereas CK2 expression and activity in a
number of solid tumors are more defined, its function in
blood cancers is less understood [21]. Kim et al. reported
that CK2α is highly expressed in a fraction of cytogeneti-
cally normal AML cases and sustains the activation of sev-
eral pro-survival signaling pathways, since CK2 inhibitors
caused AML blast apoptosis [22]. In the present study, we
further investigated CK2 expression in a series of AML
cases at diagnosis grouped according to the European
LeukemiaNet classification [23]. We analyzed the effects
of its inhibition in p53 wild-type and mutated AML cell
lines and addressed the outcome on anthracycline-driven
cytotoxicity. We show that CK2 controls AML cell sur-
vival, modulates AML cell sensitivity to daunorubicin and
impinge on the p53 and STAT3 survival regulating signal-
ing pathways.
Results
Expression levels of CK2 in AML cells
CK2 is over expressed in several solid tumor cells. Kim
et al. reported high expression of CK2 also in a subset of
AML [22]. In this report, AML cases were grouped
according to normal and abnormal karyotype and no differ-
ential CK2 expression was observed among the subgroups
with abnormal karyotype. Here, we analyzed CK2 expres-
sion in AML cell lines and AML cells from patients classi-
fied according to the European LeukemiaNet (ELN)
classification, which distinguishes different prognostic
groups according to cytogenetic alterations and mutations
to specific genes [23]. Firstly, quantitative RT-PCR was
performed in different cell lines, including K562, NB4, HL-
60 and ML2, and normal CD34+ hematopoietic cells in
order to assess CK2αmRNA levels. As shown in Figure 1A,
CK2α mRNA was much higher in AML cell lines as com-
pared to normal CD34+ hemopoietic cells. Among the dif-
ferent AML cell lines, K562 was the one displaying the
highest CK2α mRNA levels (up to fourteen-fold more as
compared to CD34+ stem cells); NB4, HL-60 and ML2
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Figure 1 CK2 expression and activity in AML cells. (A) Real-time quantitative PCR analysis of CK2α mRNA expression in a panel of AML cell
lines (K562, HL-60, NB4, ML2) and in normal CD34+ hematopoietic stem cells. (B) Top: representative western blot analysis of CK2α protein
expression in a panel of AML cell lines (K562, HL-60, NB4, ML2) and in normal CD34+ hematopoietic stem cells; bottom: corresponding
densitometric analysis. (C) In vitro kinase assay measuring CK2 kinase activity against a synthetic peptide using cell lysates from AML cell lines and
normal CD34+ hematopoietic stem cells. (D) Western blot analysis of CK2α expression in normal - or patient derived AML - peripheral blood or
bone marrow cells. Thirty-one AML cases were divided according to the European Leukemia Net classification of risk groups in favourable,
intermediate-I, intermediate-II and unfavourable. Immunoblots are shown on the upper panel while the corresponding densitometric analysis is
shown on the lower panel.
Quotti Tubi et al. Journal of Hematology & Oncology 2013, 6:78 Page 3 of 15
http://www.jhoonline.org/content/6/1/78to CD34+ cells) CK2α levels. CK2α protein levels and CK2
kinase activity were also measured in AML cell lines and
CD34+ cells (Figure 1B and C). Differently than for the
mRNA levels, CK2α protein and activity were found high
in K562, ML2 and NB4 but much lower in HL-60 cells.
Similar results were obtained when CK2α mRNA and pro-
tein levels were compared in AML cells lines and in
peripheral blood or bone marrow mononuclear cells
(Additional file 1: Figure S1). Next, by Western blot (WB)
analysis we analyzed CK2α protein expression across nor-
mal peripheral blood or bone marrow cells and primary
AML blasts from AML patients. The clinical, biological
and genetic features of the samples analyzed are summa-
rized in Table 1. As shown in Figure 1D, CK2α expression
was higher in blasts of most of the AML cases, but not all,
as compared to normal cells. These results are in accord-
ance with previous observations cited above [22]. Perhaps
due to the relatively low number of patients analyzed, we
could not detect statistically significant differences among
the different ELN AML subgroups upon quantification
and densitometric analysis. To note, due to the collection
of the samples over different times, four different blots areshown, each created and analyzed by densitometry separ-
ately. Thus, the values shown are quite different among
the four experiments.
Inhibition of CK2 activity causes AML cell apoptosis
To investigate if CK2 is important for AML cell survival,
different AML cell lines were treated with the CK2-
specific, ATP-competitive inhibitors, K27 or CX-4945.
K27 was characterized in previous studies [24] whereas
CX-4945 is a novel orally bioavailable CK2 inhibitor cur-
rently under scrutiny in phase I/II clinical trials in USA
in different solid tumors and relapsed/refractory mul-
tiple myeloma patients [25,26]. After eighteen-hours, cell
survival was analyzed by annexin V/propidium iodide
(AV/PI) staining and FACS analysis. As a control, cells
were treated with the vehicle (DMSO 0.1% in medium).
Each AML cell line displayed a different sensitivity to
CK2 inhibition. ML2, Kasumi-1 and NB4 cells resulted
extremely sensitive to CK2 inhibitors, while HL-60 cells
showed a remarkable resistance, being refractory even to
high concentrations of the inhibitors (Figure 2A and B).
Immunoblot analysis of PARP cleavage or pro-caspase 3
Table 1 Features of controls and AML cases analyzed
Sample type ELN risk group Karyotype Molecular alterations % CD 34
positive cells
1 bm Healthy donor - 46,XY - NA
2 pb AML patient Fav 46:xy NPM1, FLT3 normal, CEBPA mut 60%
3 bm AML patient Fav 46,XX,t(15;17)(q22;q11)[24]/46,XX[1] 96%
of altered methaphases
PML/RARα CD34-
4 pb AML patient Int-I 46,XY NPM1 mut (mut A), FLT3 mut CD34-
5 bm AML patient Int-I 46,XY NPM1and FLT3 normal 82%
6 pb AML patient Int-II 47,XY,+19[13]/47,XY,+del(1)(p13)[3]/46,XY[9] 64%
of altered methaphases
NPM1 mut (Mut A), FLT3 mut 52%
7 pb AML patient Int-II 46,XX,del(1)(p33)[6]/46,XX[1] 86% of altered
methaphases
NPM1 mut (mut A), FLT3 normal CD34-
8 pb AML patient Adv Complex karyotype 100% of altered
methaphases
- 78%
9 bm AML patient Adv Complex karyotype 100% of altered
methaphases
NPM1and FLT3 normal 89%
10 NB4 AML Cell line - - CD34-
11 ML2 AML Cell line - - PML/RARα CD34-
12 ME-1 AML Cell line - - - 100%
13 pb Healthy donor - 46,XY - NA
14 bm AML patient Fav 46,XY NPM1 mut (MUT K) FLT3 normal 27%
15 pb AML patient Fav 46,XY CD34-
16 bm AML patient Fav 46,XX NPM1 Mut (Mut C), FLT3 norm CD34-
17 pb AML patient Int-I 46,XY NPM1 mut (Mut A),FLT3 mut 48%
18 apheresis AML patient Int-I 46,XY NPM1 mut (Mut A),FLT3 mut 83%
19 pb AML patient Int-I 46,XX NPM1 mut (Mut B), FLT3 mut 10%
20 bm AML patient Int-I 46,XY NPM1 norm, FLT3 mut CD34-
21 pb AML patient Int-II 46,XX FLT3 mut (+75 ITD), NPM1 normal CD34-
22 pb Healthy donor - 46,XY - NA
23 pb AML patient Fav 46,XY NPM1 and FLT3 normal CD34-
24 pb AML patient Fav 46,XX NPM1and FLT3 normal CD34-
25 bm AML patient Int-I 46,XX FLT3 mut (+75 ITD), NPM1 norm 22%
26 pb AMLpatient Int-I 46,XY FLT3 mut, NPM1 norm 40%
27 pb AML patient Int-I 46,XX NPM1and FLT3 normal 72%
28 pb AML patient Int-I 46,XY NPM1 mut (mut A), FLT3 mut CD34-
29 pb AML patient Int-I 46,XX NPM1and FLT3 normal 33%
30 pb AML patient Int-II 46,XX,del(1)(p33)[6]/46,XX[1] 86%
of altered methaphases
NPM1 mut (mut A), FLT3 normal CD34-
31 bm AMLpatient Int-II 46,XY,t(12;17)(p13;q21)[9]/46,XY[1] 90%
of altered methaphases
FLT3 mut (+8 ITD), NPM1 norm 87%
32 pb AML patient adv 46,XY,der(8)t(8;?)(p11;?)[20] 100%
of altered methaphases
NPM1and FLT3 normal 89%
33 pb AML patient adv Complex karyotype 100% of altered
methaphases
NA 78%
34 pb Healthy donor - 46,XY - NA
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Table 1 Features of controls and AML cases analyzed (Continued)
35 bm AML patient Int-II 46,XY,der(8)t(8;?)(p11;?)[20] 100%
of altered methaphases
NPM1and FLT3 normal 76%
36 pb AML patient Int-II NA NA 90%
37 bm AML patient Int-II NA NA 95%
38 pb AML patient Adv NA NA CD34-
Cases were progressively numbered according to loading order in the immunoblot gels. BM = bone marrow; PB =peripheral blood; FAV = favourable; INT-I =
intermediate I; INT-II = intermediate II; ADV = adverse [according to the ELN risk stratification (Rollig et al. 2011, Journal of Clinical Oncology 29;2758)]; NA = not
assessed; MUT = mutated.
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the CK2 inhibitors triggered apoptosis in a dose-
dependent fashion in ML2 and in NB4, but not in HL-60
cells (Figure 2C and D). The efficacy of CK2 inhibition by
























































































































Figure 2 Pharmacological inhibition of CK2 causes apoptosis of AML
staining and FACS analysis in a panel of AML cell lines (NB4, ML2 and HL-60, f
CK2 inhibitors K27 (A) or CX-4945 (B). (C) Representative western blot analysi
panels), NB-4 (bottom panels) and HL-60 (top right panels) AML cell lines trea
blot analysis of PARP/cleaved PARP ratio and of phospho Ser13 CDC37 and to
(bottom left panels) and HL-60 (top right panels) and Kasumi-1 (bottom right
βactin was used to ensure equal protein loading. (E) Graph summarizing the
AML patients (n = 7; p < 0.05) untreated (un) or treated with 5 μM CX-4945 fo
cleavage in AML blasts protein lysates taken from three AML patients. Protein
untreated (Un) or upon exposure to CX-4945 5 μM. Data represent mean ± SDCDC37 phosphorylated in Ser13, which is a well-known
specific CK2 target [27] (Figure 2D). Most importantly, CX-
4945 was highly effective in causing apoptosis of blasts
obtained from AML patients, as evidenced by annexin V
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cells. (A, B) Graphs showing the rate of apoptosis assessed by annexin V
or CX-4945 also Kasumi-1) treated with increasing concentrations of the
s of PARP/cleaved PARP ratio expression in cell lysates from ML2 (top left
ted with increasing concentrations of K27. (D) Representative western
tal CDC37 expression in cell lysates from ML2 (top left panels), NB-4
panels) AML cell lines treated with increasing concentrations of CX-4945.
rate of apoptosis by annexin V staining and FACS analysis of blasts from
r 18 hours. (F) Western blot analysis of apoptosis as indicated by PARP
s were made soon after collection, at time 0 and after 18 hours of culture
, n = 3. * indicates p < 0.05.
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PARP cleavage (Figure 2F).
CK2 inhibitors-induced apoptosis is p53-dependent
The observation that HL-60 cells were refractory to the
CK2 blockade-induced apoptosis prompted us to test
whether this process could be dependent on an intact p53
tumor suppressor function. In fact, HL-60 are p53 null cells,
due to gene deletion [28] and this suggests that the AML
cell apoptosis upon CK2 inhibition could rely on p53. We
thus analyzed p53 levels in wild-type p53-expressing ML2
cells after 6 hours of treatment with 5 μM K27. Upon CK2
inhibition, p53 levels markedly increase as compared to
vehicle-treated control cells, indicating that p53 expression
and/or stability are negatively regulated by CK2 (Figure 3A).
To further support our hypothesis that CK2 inhibitionA B C
D
G H
Figure 3 CK2 controls p53 protein levels in AML cells and p53 is esse
analysis on ML2 cells treated with DMSO 0.1% (Un) or 5 μM K27 for 6 hour
densitometric analysis (n = 3; p < 0.05). (B) Top: representative WB analysis
bottom: graph summarizing annexin V staining and FACS analysis of Saos2
4945. (C) Representative WB of pro-caspase 3 and p53 levels in Saos2 cells
or pCMV-p53 expressing plasmid and treated either with DMSO 0.1% (−) o
staining/FACS analysis of Saos2 cells untransfected (Un) or transfected with
DMSO 0.1% or with 15 μM CX-4945 (D) or with DMSO 0.1% or with 10 μM
Data represent mean ± SD, n = 3. * indicates p < 0.05. (G) Top: graph sum
transfected with pCMV empty (pCMV) or pCMV-p53 plasmid and treated e
WB of p53 and pro-caspase 3 protein levels. (H) Microscope analysis of Wri
pCMV-p53 and treated either with vehicle (DMSO 0.1%) or CX-4945 7.5 μM
picnosis, blebbing or apoptotic bodies) observed in the conditions as in (H
determined to ensure equal protein loading.causes apoptosis through p53, we made use of another p53-
null cell model system, the human osteosarcoma cell line
Saos2 [29]. Saos2 cells were treated with increasing con-
centration of CX-4945 (ranging from 5 to 20 μM) and cell
viability and apoptosis were assessed by immunoblot
analysis of PARP cleavage or annexin V staining and FACS
analysis. We confirmed that also Saos2 were resistant to
CK2-inhibition induced apoptosis, since neither significant
PARP cleavage nor annexin V staining could be detected
(Figure 3B). Moreover, Saos2 cells transfected with a p53
wild-type expressing vector, but not cells transfected with an
empty vector, displayed a significantly increased sensitivity
to apoptosis induced by eighteen-hour treatment with either
CX-4945 10 μM, as shown by pro-caspase 3 reduction and
annexin V staining (Figure 3C and D) or K27 10 μM
(p < 0.05, n = 3) (Figure 3E) or by siRNA-mediated CK2αE F
I
ntial for CK2-inhibition triggered apoptosis. (A) Representative WB
s and probed with an anti-p53 antibody. Graph below: representative
of total PARP levels in Saos2 osteosarcoma cells treated with CX-4945;
cells untreated (Un) or treated with increasing concentrations of CX-
untransfected (Un) or transfected with pCMV empty-plasmid (pCMV)
r with 10 μM CX-4945. (D-F) Graphs summarizing the annexin V
pCMV empty (pCMV) or pCMV-p53 plasmid and treated either with
K27 (E) or re-transfected with scrambled or CK2-directed siRNAs (F).
marizing the data of annexin V/FACS analysis on HL-60 AML cells
ither with DMSO 0.1% or with 5 μM CX-4945; bottom: representative
ght-Giemsa stained HL-60 cells transfected with pCMV empty vector or
. (I) Quantification of morphological changes (shrinkage, nuclear
). In all the experiments, either βactin or GAPDH levels were
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of apoptosis was obtained in HL-60 AML cells transfected
with a p53 expressing vector and treated with CX-4945, as
judged by annexin V staining and FACS analysis and
immunoblot analysis of p53 (which confirmed the good
transfection efficiency) and of pro-caspase 3 levels
(Figure 3G; n = 3, p < 0.05). In these set of experiments we
also determined the transfection efficiency by employing a
pCMV-GFP vector (data not shown). Furthermore, the
morphological examination of Wright-Giemsa stained
cytological preparations (Figure 3H) and scoring of suffer-
ing/apoptotic cells (Figure 3I) also revealed that HL-60
cells’ sensitivity to CX-4945 could be recovered upon over
expression of p53. Due to transfection-related toxicity, the
basal amount of apoptosis was higher also in mock
(pCMV-vector) transfected as compared to untransfected
Saos2 and HL-60 cells.
AML cells show increased sensitivity to daunorubicin
upon CK2 inhibition
CK2 inhibition has recently been proposed as a thera-
peutic strategy to enhance the cytotoxicity of chemothe-
rapeutics [25]. Thus, we sought to investigate whether
AML cells would display an increased susceptibility to
the cytotoxic effect of the chemoterapeutic drug dauno-
rubicin, a mainstay drug in AML, in conditions of CK2
inhibition.
To this aim, ML2 cells were subjected to a combin-
ation treatment with CX-4945 or K27 at fixed poorly
toxic concentrations (5 μM and 4 μM, respectively) and
increasing doses (0.05-0.10-0.15 μM) of daunorubicin.
Annexin staining and FACS analysis revealed that AML
cell sensitivity to daunorubicin was significantly increa-
sed by CK2 inhibition either with CX-4945 or with K27
at all the concentrations of the drug tested (p < 0.05,
n = 4 or 5) (Figure 4A, representative dot plot of a FACS
analysis of CX-4945 effects and Figure 4B, graph sum-
marizing the results from the different experiments with
the two inhibitors). Also, immunoblot analysis of PARP
cleavage confirmed the cooperative pro-apoptotic effect
of CX-4945 or K27 and daunorubicin (Figure 4C). Most
importantly, we confirmed the same cooperation bet-
ween daunorubicin and CK2 inhibitors also on AML
blasts isolated from patients (n = 3 or 4), as shown in
Figure 4D for CX-4945 and Figure 4E for K27.
CK2 silencing augments AML cell sensitivity to
daunorubicin
Lastly, the results obtained with CK2 inhibitors were val-
idated upon silencing of CK2 by mean of RNA interfer-
ence. A significant down regulation of CK2α and CK2β
mRNA could be achieved in ML2 cells transfected with
CK2α or CK2β-directed siRNAs and no effects was pro-
duced by scrambled oligos (Figure 5A). Interestingly,CK2α mRNA appeared to be up regulated after CK2β
silencing. Annexin V staining assay and immunoblot
analysis of PARP cleavage demonstrated that silencing of
CK2 caused a moderate, though significant, amount of
apoptosis of ML2 cells. Most importantly, daunorubicin-
induced ML2 cell apoptosis was actually not much
enhanced upon silencing of CK2α or CK2β, but it was
remarkably boosted upon silencing of both the CK2 sub-
units (Figure 5B and C; n = 4, p < 0.05).
Synergic anti-proliferative effect between CK2 inhibitors
and daunorubicin on AML cells
To address whether the cooperation in inducing AML
cell death between CK2 inhibition and daunorubicin was
synergistic, we performed 3H-thymidine incorporation
assays evaluating the rate of cell proliferation at in-
creasing concentration of daunorubicin (range: 0.01-
0.16 μM), CX-4945 (range: 1–40 μM) and K27 (range:
1–20 μM) and the combination of daunorubicin either
with CX-4945 or K27. The results were analyzed to ob-
tain the IC50 for the three agents and the constant ratio
drug combination assay was performed, giving the com-
bination indexes (CI) according to the method described
in [30]. The results showed that treatment of ML2 AML
cells with daunorubicin and CK2 inhibitors was synergic,
as judged by the CI well below 1 (0.86 for the combin-
ation with CX-4945 and 0.7 for the combination with
K27) (Figure 6A and B, respectively).
CK2 inhibitors down modulate STAT3 activation upon
daunorubicin treatment
Previous work by others’ and our group has demon-
strated that CK2 may favour STAT3 activation [31].
STAT3 transcription factors could lend to malignant
cells the ability to escape apoptosis induced by a variety
of external stimuli, including chemotherapeutic drugs,
such as doxorubicin [32-34], and have been described to
be important in the pathogenesis of myeloid malignan-
cies [35,36]. Thus, we investigated whether CK2 could
regulate STAT3 activation and transcriptional activity,
which could account for resistance to daunorubicin in
AML cells. As shown in the representative immunoblots in
Figure 7A, daunorubicin slightly triggered STAT3 phos-
phorylation on Ser727. Remarkably, this phosphorylation
was nearly completely abrogated by the inhibition of CK2
with either 5 μM CX-4945 (top panels) or 4 μM K27
(bottom panels). The STAT3 pathway may exert its anti-
apoptotic function at least in part through the trans-
criptional up regulation of anti-apoptotic genes, like
MCL1. Moreover, a reliable STAT3 target gene is SOCS3,
a repressor of cytokine signaling which buffer down the
JAK/STAT pathway in a negative feedback loop [37-39].
The immunoblot (Figure 7A) as well as QRT-PCR analysis
(Figure 7B) of the expression of these two downstream
Figure 4 CK2 inhibition empowers doxorubicin-induced apoptosis of AML cells. (A) Representative dot plot graph depicting the rate of
apoptosis assessed by annexin V staining and FACS analysis of ML2 cells treated with two increasing concentrations of daunorubicin (0.05 and
0.15 μM) without or with a fixed dose of CX-4945 (5 μM). (B) Graphs showing ML2 AML cell apoptosis assessed by annexin V staining and FACS
analysis in the presence of increasing concentrations of daunorubicin (0.05-0.15 μM) and CX-4945 (leftmost) or K27 (rightmost) kept at the fixed
concentrations of 5 μM and 4 μM, respectively. (C) Representative immunoblot analysis of PARP cleavage in ML2 cells untreated or treated with
increasing concentrations of daunorubicin (0.05-0.15 μM) without or with a fixed subapoptotic dose of CX-4945 (5 μM, top panels) or K27 (4 μM,
bottom panels). (D, E) graphs summarizing data on the rate of apoptosis as assessed by annexin V staining and FACS analysis of freshly isolated
AML blasts treated in the presence of daunorubicin (0.05 μM), CX-4945 5 μM or both (D) or daunorubicin (0.05 μM), K27 4 μM or both (E). In all
the experiments data represent mean ± SD, n = 3-4. * indicates p < 0.05. β-actin and GAPDH were used as a protein load control in the
immunoblot experiments.
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were able to strongly down regulate the transcription and
protein expression of MCL1 and SOCS3 (Figure 7A and B)
(p < 0.05, n = 3). Thus, these results clearly suggest that
CK2 inhibition hampers the STAT3-dependent, dauno-
rubicin-elicited anti-apoptotic response in AML cells.
Discussion
We have shown here that protein kinase CK2 is highly
expressed in AML cells regulates AML cell survival and
sensitivity to daunorubicin and influences the STAT3
signaling pathway.CK2 is emerging as a critical cellular serine-threonine
kinase that regulates a large array of processes related to
cell survival and proliferation [8]. The role of CK2 in
sustaining cell in a “non-oncogene addicted” fashion
would keep oncogenic pathways constitutively activated
[20]. Most of the AML cell lines used in this study
displayed increased levels of CK2. Our data confirmed
that CK2 up regulation accompanies the transformed
phenotype in malignant hematopoietic cells and are in
agreement with what has been seen in several types of
solid tumor cell lines and tissues [20]. Importantly, CK2
in AML cells sustains survival: in fact, similarly to




























No target oligo siRNA CK2β
siRNA CK2α+β * p<0,05    n=4

































- + -- + --





























































Annexin V  





Figure 5 CK2α and CK2β silencing potentiates daunorubicin-induced AML cell apoptosis. (A) Graph summarizing the results of real time
quantitative PCR analysis of CK2α and CK2β mRNA in ML-2 cells transfected with no target scrambled oligos, CK2α or CK2β-directed siRNAs. (B)
Histogram graph (top) and dot plot graphs (bottom) summarizing annexin V and FACS analysis of the rate of apoptosis of ML-2 cells upon
transfection with no target scrambled, CK2α or CK2β-directed siRNAs without or with exposure to daunorubicin 0.15 μM or 0.25 μM. (C)
Representative immunoblot analysis of PARP cleavage and CK2α and CK2β protein levels of ML-2 cells transfected with no target scrambled, CK2α
or CK2β-directed siRNAs without or with exposure to daunorubicin 0.15 μM or 0.25 μM. In the indicated experiments data represent mean ± SD, n = 4.
* indicates p < 0.05.
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http://www.jhoonline.org/content/6/1/78previous findings from our group in multiple myeloma
cells [40] and by others [22] in AML, treatment of AML
cells with CK2 specific inhibitors determines the activa-
tion of the extrinsic and intrinsic apoptotic pathways,
and cell growth arrest (Figure 2). CK2 is known to
regulate several mechanisms associated to the extrinsic
apoptotic cascades, especially by interfering with the
extent of activation of caspase 2 downstream of Fas or
TRAIL engagement, thus protecting pro-caspase 8 from
cleavage [41-44]. CK2 also regulates the intrinsic apop-
totic pathway, even if the mechanisms involved in thisregulation are less clear [45]. Remarkably, the cytotoxic
effect of the CK2 inhibitors was also evident in freshly
isolated AML blasts from patients. Thus, the efficacy of
inducing AML cell apoptosis by CK2 inhibitors is similar
both in AML cell lines and primary AML cells.
In the present study we have also provided compelling
evidence that CK2 inhibition leads to AML apoptosis
partly in a p53-dependent fashion. In fact, the p53-mutated
HL-60 AML - as well as Saos2 osteosarcoma - cell lines
displayed refractoriness to the cytotoxic effect triggered by
CX-4945 and K27. Most importantly, restoring a normal
COMBINATION INDEX 
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Figure 6 Calculation of combination indexes indicates a synergistic cell growth arrest upon treatment of the AML cell line ML-2 with
the association of daunorubicin and CK2 inhibitors. (A) Synergistic effect of CX-4945 and daunorubicin on ML-2 cell proliferation. Left graph: dose–
response of ML-2 cells incubated for 48 hours with increasing concentrations of daunorubicin (black square) or daunorubicin plus a fixed dose (5 μM) of
CX-4945 (white circle). Right graph: dose–response of ML-2 cells incubated for 48 hours with increasing concentrations of CX-4945 (black square) or CX-
4945 plus a fixed dose (0.05 μM) of daunorubicin (white square). (B) Synergistic effect of K27 and daunorubicin on ML-2 cell proliferation. Left graph: dose–
response of ML-2 cells incubated for 48 hours with increasing concentrations of daunorubicin (black square) or daunorubicin plus a fixed dose (5 μM) of
K27 (white circle). Right graph: dose–response of ML-2 cells incubated for 48 hours with increasing concentrations of K27 (black square) or K27 plus a fixed
dose (0.05 μM) of daunorubicin (white triangle). The combination index (CI), obtained according to the formula described in the Material and Methods
section, was calculated as to be: 0.86 for the daunorubicin plus CX-4945 combination and 0.7 for the daunorubicin plus K27 combination, indicating a
synergic effect. In all the experiments data represent mean ± SD, n = 3. * indicates p< 0.01.
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http://www.jhoonline.org/content/6/1/78p53 function in HL-60 and Saos2 cells rendered these cells
prone to apoptosis induced by CK2 inhibitors (Figure 3).
The molecular relationships between CK2 and p53 are
complex and not fully understood. CK2 can phosphorylate
p53 in Ser392 upon UV light exposure and this would in-
crease p53 transcriptional activity [46,47]. However, in vivo
mouse models of CK2 over-expression showed a synergy
with p53 loss in inducing lymphomas [48]. Other studies
have also provided evidence that CK2 antagonizes p53
tumor suppressor activity (reviewed in [5]). The results
obtained in our study suggest that AML in which p53function is lost are more resistant to CK2 inhibition-
induced cell death and might not need CK2 protein over
expression or increased activity, since HL-60 did not dis-
play these features (Figure 1B and C). If this turns true also
in primary AML blasts from patients remains to be eluci-
dated. We also demonstrated that in p53 wild-type ex-
pressing AML cells, CK2 inhibition was accompanied by
an accumulation of p53, suggesting that CK2 activity
would be important for the regulation of p53 protein turn-
over in AML cells. Indeed, it is possible that CK2 down
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Figure 7 CK2 inhibition hampers STAT3 activation upon daunorubicin treatment of AML cells. (A) Representative immunoblot analysis of
phospho Ser727 STAT3 (pSTAT3 Ser727), total STAT3, MCL1, SOCS3 protein levels in ML-2 cells untreated, exposed to increasing concentrations of
daunorubicin (0.05-0.1-0.15 μM) in the absence or presence of CX-4945 5 μM (top panels) or K27 4 μM (bottom panels). (B) Real time quantitative
PCR analysis of MCL1 (lefmost panels) and SOCS3 (rightmost panels) mRNA in ML-2 cells untreated, exposed to increasing concentrations of
daunorubicin (0.05 and 0.15 μM) in the absence or presence of CX-4945 5 μM (top panels) or K27 4 μM (bottom panels). (C) Immunoblot analysis
of phospho Ser727 STAT3 (pSTAT3 Ser727), total STAT3 and MCL1 in freshly isolated AML blasts from a patient left untreated or exposed to increasing
concentrations of daunorubicin (0.05-0.1 μM) in the absence or presence of CX-4945 5 μM. In all the experiments data represent mean ± SD, n = 3.
* indicates p < 0.05.
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http://www.jhoonline.org/content/6/1/78COP9 signalosome, a multimolecular complex con-
taining CK2 and other kinases and whose role is to dir-
ect a multitude of cellular proteins towards proteaosme
mediated degradation [49].
Most importantly, we established that the anti-apoptotic
role of CK2 in AML cells is pivotal in protecting AML
cells against drug-induced apoptosis. We have shown that
daunorubicin, a widely used drug for the therapy of both
solid tumors and hematological malignancies, induces
AML cell apoptosis at a higher rate in the absence of a
functional CK2, suggesting that this kinase might regulate
anti-apoptotic signaling pathways involved in daunorubi-
cin-incuced cell death (Figures 4 and 5). The protective
effect of CK2 against daunorubicin was evident both in
AML cell lines and in AML blasts freshly isolated from
AML patients. To note, this effect was synergic (Figure 5).
We demonstrated that the STAT3 transcription factor-
regulated signaling pathway, which can be elicited upon
exposure of tumor cells to chemotherapeutics, waspartly activated by daunorubicin in AML cells (Figure 7).
Remarkably, we showed that this activation is partially
controlled by CK2. Indeed, we provided evidence that
CK2 inhibtion was associated with a drop in STAT3
phosphorylation on Ser727 and with a reduction of the
transcription of anti-apoptotic STAT3 target genes, like
MCL1. Whether CK2 directly phosphorylates STAT3 in
AML cells remains to be elucidated. Nevertheless, our
data implicate CK2 as a master regulator of the cellular
response attempting to antagonize the daunorubicin-
induced apoptosis and they show, accordingly to previous
studies (reviewed in [15]), that this kinase is essential to
maintain STAT3 transcriptional activity.
Conclusions
The data we present here reinforce the notion that CK2
might control critical signalling cascades in AML, which
could not only propel the growth of the bulk of leukemia
but also sustain the leukemia stem cell compartment.
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http://www.jhoonline.org/content/6/1/78Indeed, recent work has shown that CK2 inhibition
dampens down the PI3K/AKT pathway with a reduction
of the activity of downstream effectors such as Bcl-xl
and NF-κB and cooperates with PI3K inhibitors in
inducing cell death of CD34+ CD38- AML leukemia
stem cells [50]. Our study provides experimental evi-
dence that AML cell survival relies at least in part on an
intact CK2 function. CK2 might protect against chemo-
therapy-induced cell death through inhibition of p53 and
activation of STAT3. Therefore, the pharmacological dis-
ruption of CK2 could achieve the goal of restoring p53
function while simultaneously inhibiting STAT3 activity
[51] and could be envisioned as a complementary thera-
peutic strategy in the management of p53 wild-type/
STAT3 over expressing AML. This perspective is particu-
larly intriguing in that STAT3 has been demonstrated to
regulate leukemia stem cell but not hematopoietic stem
cell survival [52]; thus, drugs that target simultaneously
STAT3, AKT and NF-κB in AML could produce the effect
of eradicating the malignant, but not the normal, stem
cell pool.
Material and methods
Primary AML blasts, AML cell lines and cultures
Patients were charged to the University of Padova Hospital.
Written informed consent was obtained from patients
according to the declaration of Helsinki. The project
outline and consent procedures and forms were submitted
and approved by the Ethic Committee of the Padova
University Hospital (protocol number 2612P). Samples
from healthy subjects and AML blasts from peripheral
blood (PB) and bone marrow (BM) were processed as per
standard protocols. From PB blasts were enriched after
sheep red blood cells-mediated T-cell depletion. Cases
were used when blasts were superior to 80% of total cells.
AML cell lines NB-4, ML-2, HL-60 and KASUMI-1 were
maintained in RPMI 1640 medium supplemented with L-
glutamine, antibiotics (penicillin and streptomycin) and
10% or 20% fetal bovine serum (FBS) according to manu-
facturer’s datasheet (Gibco Laboratories, Grand Island, NY,
USA). Saos2 cells were grown in DMEM with 10%
FBS. All cell lines were kept under controlled atmos-
phere at 37°C in the presence of 5% CO2.
Cell cultures were periodically checked for Mycoplasma
contamination.
Chemicals
CK2 inhibitor K27, a TBB-derivative, (2-amino-4,5,6,
7-tetrabromo-1H-benzimidazole) was synthesized and
kindly provided by Dr Z. Kamizierczuk (Warsaw, Poland);
CX-4945 was purchased from Activate Scientific GmbH.
Daunorubicin (purchased from Pfizer) was provided
by the University of Padua Hospital, Department of
Medicine.Evaluation of growth and apoptosis
Apoptosis was assessed by fluorescein isothiocyanate
(FITC)-Annexin V/Propidium iodide staining (BD Phar-
mingen) or in separate experiments, by detection of
mitochondrial membrane potential using 5,5′,6,6′, tetra-
chloro 1,1′,3,3′-tetraethylbenzimidazolyl carbocyanin
iodide dye (JC-1) (Trevigen, Germany) according to the
manufacturer’s instructions. Samples stained with Annexin
V/Propidium Iodide or JC-1 were then analyzed by flow
cytometry with FACScalibur and CellQuest (Beckton
Dickinson) or FlowJo analytic softwares. In order to calcu-
late the combination index, using the Chou-Talalay
method [53], the IC50 values of different agents were
calculated. For this purpose [3H]thymidine incorporation
assays were performed. AML cells were seeded in 96-well
plates (8×104/well) with different concentration of CK2 in-
hibitors (K27 or CX-4945) or daunorubicin. After 40 hours
[3H]thymidine was added to the cultures (10 μCi/well) for
at least 8 h. The [3H]thymidine incorporation was evaluated
by scintillation counting by using a β-counter (Microbeta
Plus, Wallac). The IC50 concentrations of single agents
were combined by keeping a fixed ratio for the treatment
of AML cells.
CK2 activity in cell lysates
CK2 activity was measured on the R3AD2SD5 peptide
substrate, as previously described [40].
RNA interference, plasmids and transfection
RNA interference was performed using small interfering
RNAs purchased from Dharmacon, USA: ML-2 and HL-
60 cells (2 × 106), Saos2 (1 × 106) in log phase of growth
were nucleofected with the Amaxa system kit V (using
L-029 program for ML-2, X-001 program for HL-60 and
Saos2); cells were transfected with 100 pmol siGLO
Green scrambled siRNA (as marker of transfection
efficiency), control siRNA pool (no targeting pool) or




target sequences were: CAACCAGAGUGACCUGAUU;
GCAAGGAGACUUUGGUUAC; GCAAUGAAUUCU
UCUGUGA; CCAAGUGCAUGGAUGUGUA). Cells
were immediately put in pre-warmed RPMI or DMEM
media and left in culture for 72 hours. In the dauno-
rubicin treatment experiments, cells were exposed to
the chemical after 48 hours from transfection and col-
lected 18 hours later. HL-60 and Saos2 cell lines were also
transiently transfected with the empty pCMV plasmid
vector or pCMV-p53 wild-type expression vector (kind gift
of Dr. P.P. Pandolfi, Harvard University, MA, USA); HL-60
were nucleofected by means of the Amaxa system® using
1 μg of each plasmid, Saos2 were transfected through
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http://www.jhoonline.org/content/6/1/78lipofectamine 2000 (Invitrogen, Carlsbad, CA) using 3 μg of
each plasmid and a DNA/lipofectamine ratio of 1:2.5. The
over expression of p53 was then evaluated by western blot
analysis. After 48 hours from transfection with pCMV o
pCMV-p53 vectors cells were treated for 18 hours with
CK2 chemical inhibitors or transfected with scrambled or
CK2α-specific siRNA oligos.
Microscopy
HL-60 cells (8 × 104) were spotted on glass slides through
citospin and then stained with May-Grünwald/Giemsa
method: 3′ in pure May-Grünwald; 3′ in May-Grünwald
diluted 1:2 v/v in water, 20′ in Giemsa diluted 20% v/v in
water, final wash in water. Samples were analysed by means
of Olympus CX-41 microscope at 20× magnification.
Western blot and antibodies
Whole cell extracts (WCE) were obtained by lysis with
20 mM Tris (pH 7.5), 150 mM NaCl, 2 mM EDTA, 2 mM
EGTA supplemented with 0,5% Triton X-100 (Sigma-
Aldrich), protease inhibitor cocktail (Sigma-Aldrich),
phosphatase inhibitor cocktail (Thermo Scientific), 1 mM
phenyl-methyl-sulfonyl fluoride (PMSF; Sigma-Aldrich),
1 μM okadaic acid (Sigma-Aldrich). Twenty to 50 μg of
WCE were subjected to SDS-PAGE, transferred to nitro-
cellulose or PVDF membranes and immunoblotted with
the following primary antibodies: CK2α-subunit rabbit
antiserum raised against the (376–3919) region of human
protein (kindly provided by Dr S. Sarno, University of
Padua, Italy); anti-PARP, anti-STAT3 and phospho-Ser727-
STAT3, anti-MCL1 (Cell Signaling, Beverly, MA); anti-
SOCSs3 and anti-CDC37 (Santa Cruz Biotechnology,
Santa Cruz, CA) anti-phospho-Ser13 CDC37 (Abcam);
anti-caspase 3 (Calbiochem-Merck Biosciences, bad Soden,
Germany); anti-p53 and CK2β (BD Biosciences, USA);
βactin (Sigma-Aldrich), GAPDH (Ambion). As secondary
antibodies: anti-rabbit IgG HRP-linked antibody (Cell
Signaling, Beverly, MA); HRP labeled goat anti-mouse IgG
(KPL, Gaithersburg, MD, USA). Detection was performed
using ECL (Pierce, Thermo Scientific), Super Signal West
Pico Chemiluminescent Substrate (Pierce, Thermo Scien-
tific) or LiteAblot Extend Long Lasting Chemiluminescent
Substrate (Euroclone) according to manufacturer’s instruc-
tion. Densitometric analysis was conducted using Quantity
One Software (Biorad).
Real-time quantitative PCR
cDNA (50 ng) was subjected to real-time RT-PCR using
SYBR Green Reagents (Invitrogen) according to manufac-
turer’s protocol. The incorporation of SYBR Green Dye
into the PCR products was monitored in real-time with
ABI PRISM 7000 detection system (Applied Biosystem).
Target genes were quantified relative to a reference gene,
glyceraldehydes-3-phosphate dehydrogenase (GAPDH),which expression was stable in our experimental condi-
tion. Primer sequences are the following ones: CK2α (F:
TCATGAGCACAGAAAGCTACGA) (R: AATGGCTCC
TTCCGAAAGATC; CK2β (F: CCCATTGGCCTTTCAG
ACAT) (R: CCGTGTGATGGTGTCTTGATG); MCL-1(F:
GAAAGTATCACAGACGTTCTCGTAAGG) (R:AACCC
ATCCCAGCCTCTTTG); SOCS3 (F: CAGCTCCAAG
AGCGAGTACCA) (R: AGAAGCCGCTCTCCTGCAG);
GAPDH (F: AATGGAAATCCCATCACCATCT; (R: CGC
CCCACTTGATTTTGG);Statistical analysis
Statistical significance of data was evaluated with the
2-tailed paired Student t test or analysis of variance
(ANOVA) with post-hoc corrections. Results were con-
sidered statistically significant at p values below 0.05.Additional file
Additional file 1: Figure S1. CK2 expression and activity in AML cell
lines and normal mononuclear cells. (A) Real-time quantitative PCR
analysis of CK2α mRNA expression in a panel of AML cell lines (K562,
HL-60, NB4, ML2) and in normal peripheral blood (pb) cells. (B) Top:
representative western blot analysis of CK2α protein expression in a
panel of AML cell lines (K562, HL-60, NB4, ML2) and in normal peripheral
blood (pb) or bone marrow (bm) cells; bottom: graph showing the
corresponding densitometric analysis.Competing interests
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